相关实验视频
Updated: Sep 15, 2025

11:12
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
22.6K
在帕金森病的非运动症状适应性深度大脑刺激方面?
Bart E K S Swinnen1, Colin W Hoy1, Simon J Little1
1UCSF Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
概括
帕金森病 (PD) 的深度大脑刺激 (DBS) 主要针对运动症状. 新的自适应性DBS (aDBS) 策略可以解决残疾非运动症状,改善患者的生活质量.
科学领域:
- 神经学 神经学
- 神经科学是一个神经科学.
- 生物医学工程 生物医学工程
背景情况:
- 非运动性症状显著影响帕金森病患者的生活质量.
- 目前PD的深度大脑刺激 (DBS) 主要针对运动缺陷,对非运动症状的有效性有限.
- 专门针对非运动性PD症状的神经调节仍然在很大程度上未被探索.
研究的目的:
- 综合审查DBS对非运动性PD症状的影响.
- 讨论DBS诱导的非运动性副作用,如冷漠和躁狂.
- 通过新兴传感技术,为非机动PD提出可行的自适应DBS (aDBS) 策略.
主要方法:
- 对PD的DBS现有文献的审查,重点关注非运动结果.
- 对PD非运动症状的神经解剖学和时间动态的分析.
- 基于可传感的DBS设备的非机动aDBS策略的概念化.
主要成果:
- DBS对非运动性PD症状的影响不足.
- DBS可以诱导非运动性副作用,包括冷漠和低迷.
- 新兴的感应DBS技术使得对非运动症状的响应性神经调节成为可能.
结论:
- 适应性DBS (aDBS) 为治疗非运动性PD症状提供了一个有希望的途径.
- 关键的挑战包括生理标志物验证,算法优化,技术创新和道德考虑.
- 本综述为PD中开发非机动aDBS提供了一份路线图.
更多相关视频
相关概念视频
Parkinson's Disease: Treatment
381
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
381
Parkinson's Disease: Overview
713
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
713

